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Abstract The three genes hTAFII68, EWS, and TLS (called
the TET family) encode related RNA binding proteins contain-
ing an RNA recognition motif and three glycine-, arginine-, and
proline-rich regions in the C-terminus and a degenerated repeat
containing the consensus sequence Ser-Tyr-Gly-Gln-Ser in the
N-terminus. In many human cancers, the N-terminal portion of
hTAFII68, EWS, or TLS is fused to the DNA binding domain
of one of several transcription factors including Fli-1, ERG,
ETV1, E1AF, WT1, ATF-1, CHOP, or TEC. We have recog-
nized the presence of several potential tyrosine phosphorylation
sites within the amino-terminal domain of hTAFII68 and have
investigated the potential e¡ects of cytoplasmic signaling on
hTAFII68 function. Herein, we ¢nd that hTAFII68 is phosphor-
ylated on tyrosine residue(s) by ectopic expression of v-Src pro-
tein tyrosine kinase in vitro and in vivo. The hTAFII68 protein
can associated with the SH3 domains of several cell signaling
proteins, including v-Src protein tyrosine kinase. We also docu-
ment that full-length v-Src can stimulate hTAFII68-mediated
transcriptional activation, whereas deletion mutants of v-Src
are unable to exert this e¡ect. In addition, cellular Src activity
appears important for hTAFII68 function since hTAFII68-medi-
ated transactivation is reduced in a dose-dependent fashion by
ectopic overexpression of a dominant-negative mutant of Src.
Taken together, our results suggest that the biological activities
of hTAFII68 are linked to the cytoplasmic Src signal transduc-
tion pathway.
6 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Molecular characterization of speci¢c chromosome abnor-
malities associated with human tumors has led to the discov-
ery of new mechanisms involved in neoplastic transformation.
Chromosomal rearrangements are very common molecular
abnormalities in hematologic malignancies. These rearrange-
ments consist mainly of chromosomal translocations and, less
frequently, chromosomal inversions which can lead to neo-
plastic malignancy by two di¡erent mechanisms: (i) the tran-
scriptional activation of proto-oncogenes, or (ii) the creation
of fusion genes [1,2]. In some leukemias and lymphomas, the
juxtaposition of promoter or enhancer elements from immu-
noglobulin genes with the intact coding region of other genes,
such as c-myc, bcl-2, bcl-6 etc., determines the neoplastic phe-
notype by altering cell cycle progression, halting the physio-
logic process of apoptosis, or modifying lineage-speci¢c tran-
scription [3]. In chronic myeloid leukemia, bcr fuses with c-abl
to generate the bcr-abl chimeric transcript. This transcript en-
codes a fusion protein of 210 kDa with increased tyrosine
kinase activity and abnormal cellular localization [4,5].
Unlike in hematologic malignancies, however, recurrent
chromosome rearrangements are relatively uncommon in solid
tumors. A rare exception is the Ewing’s sarcoma gene (EWS),
which is translocated in a wide variety of human solid tumors.
In each translocation case, fusions of the N-terminal domain
(NTD) of EWS to novel DNA binding domains create chi-
meric proteins with altered transactivation potential [6^16].
The EWS gene encodes a 656 amino acid protein that con-
tains three arginine-rich tracts and an 85 amino acid RNA
recognition motif at its C-terminus. The EWS (NTD) is com-
posed almost exclusively of tyrosine, glutamine, glycine, ala-
nine, serine, threonine, and proline residues organized in a
repeated and degenerated polypeptide motif having the con-
sensus NSYGQQS. Interestingly, this domain shares distant
homology with the C-terminal domain of eukaryotic RNA
polymerase II [7].
Human TATA binding protein (TBP)-associated factor 68
(hTAFII68) encodes a putative RNA/ssDNA binding protein
and was originally identi¢ed due to its homology to the proto-
oncogenes EWS and TLS (another member of the EWS gene
family) [17,18]. Recently, a proportion of extraskeletal myxoid
chondrosarcomas have been shown to harbor a characteristic
translocation t(9;17)(q22;q11.2) involving the hTAFII68 gene
at 17q11.2 and the TEC (Translocated in Extraskeletal
Chondrosarcoma) gene at 9q22 [19,20]. TEC (also called
CHN and MINOR) is the human homologue of the rat
NOR-1 receptor [21] and encodes a novel orphan nuclear
receptor belonging to the steroid/thyroid receptor gene super-
family [22,23].
The Src family of tyrosine kinases is composed of nine
members in higher eukaryotes of which three, Src, Yes, and
Fgr, have viral counterparts. v-Src, the ¢rst viral form iden-
ti¢ed, is the transforming product of the chicken retrovirus,
Rous sarcoma virus [24,25]. The Src family of non-receptor
protein tyrosine kinases plays critical roles in a variety of
cellular signal transduction pathways, regulating such diverse
processes as cell division, motility, adhesion, angiogenesis, and
survival. Constitutively activated variants of Src family ki-
nases, including the viral oncoproteins v-Src and v-Yes, are
capable of inducing malignant transformation in a variety of
cell types. Although exactly how Src family tyrosine kinases
contribute to individual tumors remains to be de¢ned com-
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pletely, they appear to be important for multiple aspects of
tumor progression, including proliferation, disruption of cell^
cell contacts, migration, invasiveness, resistance to apoptosis,
and angiogenesis [26].
Signal transduction pathways can regulate gene expression
by modulating the activity of nuclear transcription factors
[27,28]. We have previously shown that ectopic expression
of v-Src phosphorylates EWS/WT1 in vivo, as well as enhanc-
ing the transactivation ability of the EWS NTD [29]. How-
ever, tyrosine phosphorylation of EWS/WT1 by c-Abl nega-
tively regulates its DNA binding properties [30]. Interestingly,
it has been reported that many signaling proteins, such as
Ras, Btk, RET/PTC, and v-Src, enhance the transcriptional
activity of several transcription factors, such as AP-1, TFII-I,
and STAT3 [31^39]. We show herein that hTAFII68 (NTD) is
phosphorylated on tyrosine residue(s) by ectopic expression of
v-Src protein tyrosine kinase in vitro and in vivo. We also
de¢ne the interaction between hTAFII68 (NTD) and v-Src
in vivo. Furthermore, the transactivation activity of hTAFII68
(NTD) is positively regulated by v-Src, but negatively modu-
lated by a dominant-negative form of v-Src. These data im-
plicate the Src signaling pathway in hTAFII68 (NTD)-medi-
ated transcriptional activation.
2. Materials and methods
2.1. Materials and general methods
Restriction endonucleases, polynucleotide kinase, calf intestinal
alkaline phosphatase, the Klenow fragment of DNA polymerase I,
and T4 DNA ligase were purchased from New England Biolabs.
[Q-32P]ATP (3000 Ci/mmol) and [35S]methionine (1000 Ci/mmol)
were obtained from Amersham. Preparation of plasmid DNA, restric-
tion enzyme digestion, agarose gel electrophoresis of DNA, DNA
ligation, bacterial transformations, and sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) of proteins were carried
out using standard methods [40].
2.2. Plasmid constructions
To generate glutathione S-transferase (GST)-hTAFII68 (NTD), the
NTD of hTAFII68 (obtained from Dr. L. Tora, Institut de Ge¤ne¤tique
et de Biologie Mole¤culaire et Cellulaire, CU de Strasbourg, France)
was ampli¢ed by polymerase chain reaction (PCR) using primer 5P-
TAFII68-1A (5P-GATCGGATCCATGTCGGATTCTGGAAGT-3P)
and primer 3P-TAFII68-477 (5P-GATCCTCGAGTCAATCTTGTG-
TGTGGTGGCT-3P), digested with BamHI and XhoI, and cloned
into the same sites of pGEX(4T-1) (Pharmacia Biotech). To construct
pTRCWHisA-v-Src, the BamHI fragment of pcDNA3/v-Src was sub-
cloned into the BamHI site of pTRCWHisA vector (Invitrogen). For
His6-Flag-hTAFII68 (NTD), the NTD of hTAFII68 was generated by
PCR using primer 5P-TAFII68-1B (5P-GATCGGATCCCATGTCG-
GATTCTGGAAGT-3P) and primer 5P-TAFII68-476 (5P-GATC-
CTGCAGTCTTGTGTGTGGTGGCT-3P), digested with BamHI
and PstI, and cloned into the same sites of pCMV-Tag2A (Stratagene)
to generate pCMV-Tag2A-hTAFII68 (NTD). Then, the NotI-HindIII
fragment of pCMV-Tag2A-hTAFII68 (NTD) was subcloned into the
NotI and HindIII sites of pcDNA3.1 mycWhis B(3) (Invitrogen). De-
tails on the construction of GST-EWS (NTD) have been described
previously [30]. To generate GST-TLS (NTD), the NTD of TLS
(kindly provided by Dr. T. Okamoto, Nagoya City University Med-
ical School, Nagoya, Japan) was ampli¢ed by PCR using primers 5P-
TLS-1 (5P-GATCGGATCCATGGCCTCAAACGATTAT-3P) and 3P-
TLS-265 (5P-CTAGCTCGAGTCAACCAAATTTATTGAAGCC-3P),
digested with BamHI and XhoI, and cloned into the same sites of
pGEX(4T-1). The construction of pcDNA3/GST has been previously
described [30]. pcDNA3/GST-hTAFII68 (NTD) was made by isolating
an EcoNI and XhoI fragment from pGEX(4T-1)-hTAFII68 (NTD)
and cloned into the same sites of pcDNA3/GST.
GST fusion plasmids GST-hTAFII68 (1^72), GST-hTAFII68 (29^
105), and GST-hTAFII68 (75^159) were generated by the following
strategies. (A) For GST-hTAFII68 (1^72), plasmid pGEX(4T-1)-
hTAFII68 (NTD) was digested with SacI and XhoI, blunted with
the Klenow fragment, and then self-ligated. This construct was di-
gested with NotI, treated with the Klenow fragment, and self-ligated
to generate an in-frame stop codon. (B) For GST-hTAFII68 (29^105),
plasmid pGal4-hTAFII68 (NTD) was digested with BamHI and BstXI
and self-ligated. This construct was then re-digested with XcmI and
PstI and self-ligated. The newly generated construct was then digested
with EcoRI, the excised fragment blunted with Klenow fragment, and
ligated into the blunted BamHI and XhoI sites of pGEX(4T-1). (C)
For GST-hTAFII68 (75^159), plasmid pGal4-hTAFII68 (NTD) was
digested with BamHI and SacI, repaired with the Klenow fragment,
and self-ligated. This new construct was digested with EcoRI and
XbaI, the excised fragment blunted with the Klenow fragment, and
then ligated into the blunted BamHI and XhoI sites of pGEX(4T-1).
To generate Gal4-hTAFII68 (NTD), the NTD of hTAFII68 was
ampli¢ed by PCR using primer 5P-TAFII68-1C (5P-GATCGGATCC-
GAATGTCGGATTCTGGAAGT-3P) and primer 3P-TAFII68-476
(5P-GATCCTGCAGTCTTGTGTGTGGTGGCT-3P), digested with
BamHI and PstI, and cloned into the same sites of the pM vector
(Clontech). Descriptions of plasmids encoding GST fusions contain-
ing SH3 domains from various kinases and adapter molecules, as well
as of the mammalian expression v-Src constructs (pcDNA3-v-Src,
vkinase, and R295) have been previously described [29].
2.3. Puri¢cation of His6-tagged v-Src
The recombinant pTRCWHisA-v-Src plasmid was transformed into
Escherichia coli, the expression of His6-v-Src was induced by isopro-
pyl-L-D-thiogalactopyranoside, and the recombinant protein was pu-
ri¢ed by chromatography on Ni-nitrilotriacetic acid (NTA)-agarose
according to the supplier’s protocol (Qiagen). Brie£y, the cell pellet
from a culture was resuspended in lysis/wash bu¡er (50 mM Tris^HCl
pH 8.0, 300 mM NaCl, 10 mM imidazole), clari¢ed by centrifugation
(16 000 rpm for 15 min) at 4‡C, and the supernatant was incubated
with NTA-agarose resin for 1 h at 4‡C on a slowly rotating wheel.
The protein-bound NTA-agarose resin was then packed into a Micro
Bio-Spin chromatography column (Bio-Rad) and washed extensively
with lysis/wash bu¡er. The protein was eluted with elution bu¡er
(50 mM Tris^HCl pH 8.0, 300 mM NaCl, 20 mM imidazole). Puri¢ed
v-Src kinase activity was assessed using myelin basic protein (Sigma)
as a substrate in an in vitro kinase assay.
2.4. In vitro kinase assay and phosphoamino acid analysis
Bacterially produced GST or GST-hTAFII68 (NTD) were incubat-
ed with recombinant His6-v-Src protein with 50 WM ATP and 10 WCi
of [Q-32P]ATP (3000 Ci/mmol) in a reaction mixture for 20 min at
30‡C. Reaction mixtures were resolved on a 15% SDS^PAGE and
labeled proteins were visualized by exposing the dried gel to X-ray
¢lm (Kodak). For phosphoamino acid analysis of phosphorylated
hTAFII68 (NTD) by v-Src, acid hydrolysates of phosphorylated
GST-hTAFII68 (NTD) were prepared and fractionated by electropho-
resis on thin layer cellulose at pH 1.9 (0.58 M formic acid, 1.36 M
acetic acid) and pH 3.5 (0.87 M acetic acid, 0.5% v/v pyridine, 0.5 mM
EDTA) using the Hunter Thin Layer Peptide Mapping Electrophore-
sis System1 (C.B.S. Scienti¢c) according to the manufacturer’s in-
struction. Non-radioactive standards were visualized by staining
with 0.25% ninhydrin in acetone and labeled amino acids were de-
tected by autoradiography.
2.5. In vitro transcription and translation
In vitro transcriptions and translations were performed in the pres-
ence of [35S]methionine in rabbit reticulocyte lysates using the TNT
T7 coupled reticulocyte system, essentially as described by the manu-
facturer (Promega).
2.6. GST pull-down assays
GST or GST fusion proteins were expressed in bacteria and ad-
sorbed onto glutathione-agarose. The resin was then incubated at 4‡C
for 1 h with [35S]methionine-labeled hTAFII68 (NTD) or v-Src or
recombinant His6-tagged proteins. Agarose beads were washed three
times with wash bu¡er (50 mM Tris^HCl pH 8.0, 150 mM NaCl,
2 mM EDTA, 0.1% NP-40, 10% glycerol), and the bound proteins
were eluted with SDS loading bu¡er (62.5 mM Tris^HCl pH 6.9, 10%
glycerol, 2% SDS, 5% L-mercaptoethanol) and resolved by SDS^
PAGE. Bound proteins were detected using autoradiography or im-
munoblotting as previously described [29].
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Fig. 1. Tyrosine phosphorylation of hTAFII68 (NTD). A: Putative tyrosine phosphorylation sites in hTAFII68 (NTD). The presence of 13
potential tyrosine phosphorylation sites is indicated by a bold character and underscores within the sequence. The pY prediction score is the
output score from the ensemble of the neural networks trained on that acceptor residue type (performed at http://www.cbs.dtu.dk/services/
NetPhos/). The sequence shows the context of the acceptor residue £anked on each side by four residues. B: In vitro phosphorylation of
hTAFII68 (NTD) by v-Src. One microgram of GST or GST-hTAFII68 (NTD) was incubated with recombinant His6-v-Src protein with 50 WM
ATP and 10 WCi of [Q-32P]ATP (3000 Ci/mmol) in a reaction mixture for 20 min at 30‡C. Reaction mixtures were resolved on 15% SDS^
PAGE and labeled proteins were visualized by exposing the dried gel to X-ray ¢lm (Kodak). The presence of v-Src, GST, or GST-hTAFII68
(NTD) in each incubation is indicated above the lanes. The position of migration of the GST-hTAFII68 (NTD) or GST is indicated. Molecular
mass markers are provided to the left and are derived from prestained protein standards (New England Biolabs). C: In vitro kinase assay with
a series of hTAFII68 (NTD) deletion mutants. Reaction mixtures were resolved on 15% SDS^PAGE and labeled proteins were visualized by ex-
posing the dried gel to X-ray ¢lm (Kodak). The presence of v-Src, GST, or GST-hTAFII68 (NTD) deletion mutants in each incubation is indi-
cated above the lanes. The presence of tyrosine phosphorylation was detected with an anti-phosphotyrosine antibody (4G10). The position of
migration of the GST-hTAFII68 (NTD) deletion mutants or GST is indicated by arrowheads. Molecular mass markers are provided to the left
and are derived from prestained protein standards (New England Biolabs). D: Phosphoamino acid analysis of in vitro phosphorylated
hTAFII68 (NTD) by v-Src. Phosphorylated GST-hTAFII68 (NTD) was separated by 15% SDS^PAGE, transferred onto Immobilon PVDF
membrane, and GST-hTAFII68 (NTD) identi¢ed by autoradiography. Hydrolysis was performed in 6 M HCl at 110‡C for 1 h, after which
time 1 ml of water was added and the samples lyophilized. Samples were analyzed using Hunter Thin Layer Peptide Mapping Electrophoresis
System1 (bottom panel). The same molecular mass region was also excised from the PVDF membrane, which contained extract prepared from
GST alone (top panel). E: In vivo tyrosine phosphorylation of hTAFII68 (NTD) by v-Src. A mammalian expression plasmid encoding His6-
tagged Flag-hTAFII68 (NTD) and either v-Src or the empty vector (pcDNA3) was cotransfected into COS-7 cells. Forty-eight hours after
transfection, His6-Flag-hTAFII68 (NTD) protein was puri¢ed using Ni-NTA-agarose, separated by 10% SDS^PAGE, and transferred onto Im-
mobilon PVDF membrane. The presence of hTAFII68 (NTD) protein was con¢rmed with an anti-Flag antibody (top panel) and tyrosine phos-
phorylation was detected with an anti-phosphotyrosine antibody (4G10) (bottom panel).
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2.7. Co-a⁄nity precipitations
Plasmid pcDNA3/v-Src was cotransfected into mammalian cells
with either pcDNA3/GST or pcDNA3/GST-hTAFII68 (NTD). After
48 h, cells were harvested in resuspension bu¡er (50 mM Tris^HCl pH
8.0, 2 mM EDTA, 1% NP-40, 1UComplete Protease Inhibitor Cock-
tail Solution (Roche Diagnostics)) and lysed by sonication. Superna-
tants were collected by centrifugation at 16 000Ug for 15 min at 4‡C
and incubated with glutathione beads (Amersham Biosciences) for 1 h.
The beads were collected by brief centrifugation and washed with
resuspension bu¡er four times. The a⁄nity-selected proteins were
eluted in SDS loading bu¡er (62.5 mM Tris^HCl pH 6.9, 10% glyc-
erol, 2% SDS, 5% L-mercaptoethanol) and fractionated by SDS^
PAGE.
2.8. Western blot analysis
COS-7 cells were lysed in lysis bu¡er (50 mM sodium phosphate pH
8.0, 300 mM NaCl, 10 mM imidazole, 1UComplete Protease Inhib-
itor Cocktail Solution), lysates were heated to 95^100‡C for 5 min,
and equal amounts of protein were loaded onto SDS^polyacrylamide
gels. Gels were electrotransferred onto polyvinylidene di£uoride
(PVDF) membranes, treated with a blocking bu¡er (20 mM Tris^
HCl pH 7.5, 137 mM NaCl, 0.1% Tween-20, 5% w/v non-fat dried
milk) for 1 h at room temperature, and incubated with the primary
antibody (anti-£ag M2 monoclonal antibody (Sigma)) for 1 h at room
temperature. After three washes in TBST (20 mM Tris^HCl pH 7.5,
137 mM NaCl, 0.1% Tween-20), membranes were incubated with the
horseradish peroxidase-conjugated secondary antibody (goat anti-
mouse IgG (Santa Cruz Biotechnology)) in blocking bu¡er for 1 h
at room temperature. Detection was performed by chemiluminescence
using Western Lightening (Perkin-Elmer Life Sciences).
2.9. Cell culture, electroporation and reporter assays
C33A or 293T cells were maintained in Dulbecco’s modi¢ed Eagle’s
medium supplied with 10% heat-inactivated fetal calf serum (Gibco
BRL), penicillin, and streptomycin. C33A or 293T cells were tran-
siently transfected with plasmids by electroporation using the Gene
Pulser II RF module system according to the manufacturer’s instruc-
tion (Bio-Rad). Luciferase assays were performed with the Promega
Luciferase Assay System or Dual-luciferase Assay System according
to the supplier’s protocol (Promega). L-Galactosidase or Renilla lucif-
erase activities were used to normalize the transfection e⁄ciency.
2.10. Subcellular localization experiment
Immunocytochemical analyses were performed as previously de-
scribed [41]. Brie£y, COS-7 cells were plated on glass coverslips and
transfected with the indicated DNA plasmids using FuGene (Roche
Diagnostics) following the manufacturer’s instructions. At 48 h post
transfection, the cells were washed in phosphate-bu¡ered saline (PBS)
and ¢xed for 10 min at 320‡C with acetone/methanol (1:1, v/v). For
hTAFII68-TEC detection, anti-Flag antibody and secondary antibody
conjugated with rhodamine (Sigma) were used. The coverslips were
mounted with 50% glycerol/PBS. Fluorescence was detected with a
£uorescence microscope (Olympus, 1X51) equipped with a CoolSNAP
digital camera (Olympus).
3. Results
3.1. hTAFII68 is a phosphotyrosine protein
The NTD of human hTAFII68 is fused to the orphan fam-
ily nuclear receptor TEC in extraskeletal myxoid chondrosar-
coma and the encoded product likely acts as a transcriptional
activator [19,42]. This domain is composed almost exclusively
of tyrosine, glutamine, alanine, serine, threonine, glycine, and
proline residues and shares homology with the amino-terminal
domain of the EWS proto-oncoprotein [17,43]. Because the
NTD of EWS has been previously shown to contain several
potential tyrosine phosphorylation sites [29,30], we assessed if
this was also the case for hTAFII68. Interestingly, analysis of
the hTAFII68 (NTD) protein sequence (performed at http://
www.cbs.dtu.dk/services/NetPhos/) revealed the presence of 13
potential tyrosine phosphorylation sites (Fig. 1A).
To assess the functional signi¢cance of these sites, we per-
formed in vitro kinase assays utilizing recombinant v-Src and
found that this caused phosphorylation of GST-hTAFII68
(NTD) (Fig. 1B). Recombinant GST was not a substrate for
v-Src phosphorylation (Fig. 1B), establishing that phosphor-
ylation occurs within the hTAFII68 (NTD) part of the fusion
protein. These results demonstrate that GST-hTAFII68
(NTD) is a substrate of Src kinase in vitro.
In order to better de¢ne the phosphorylation site(s) of v-Src
on the hTAFII68 (NTD), we also carried out an in vitro ki-
nase assay with a series of hTAFII68 (NTD) deletion mutants.
Consistent with the prediction from the analysis of the puta-
tive tyrosine phosphorylation sites in hTAFII68 (NTD) (Fig.
1A), in vitro incubation of GST-hTAFII68 (1^72), hTAFII68
(29^105), and hTAFII68 (75^159) with recombinant v-Src pro-
tein kinase resulted in the phosphorylation of all three
hTAFII68 (NTD) truncation mutants (Fig. 1C).
To identify the amino acid acceptor of hTAFII68, we per-
formed phosphoamino acid analyses. Acid-hydrolyzed sam-
ples were spotted onto a TLC plate and the components sep-
arated by two-dimensional electrophoresis utilizing pH 1.9 in
the ¢rst dimension and pH 3.5 in the second dimension. This
analysis revealed that the site(s) phosphorylated by v-Src is/
are tyrosine residue(s) (Fig. 1C).
To determine whether hTAFII68 (NTD) is a substrate of
the Src protein tyrosine kinase in vivo, a plasmid encoding
His6-Flag-tagged hTAFII68 (NTD) was cotransfected into
COS-7 cells with an expression plasmid driving synthesis of
v-Src. Forty-eight hours after transfection, cells were lysed
and His6-Flag-tagged hTAFII68 (NTD) proteins were a⁄n-
Fig. 2. Interaction between hTAFII68 (NTD) and v-Src in vitro. A:
Association of v-Src with the NTDs of EWS, TLS, or hTAFII68.
[35S]Methionine-labeled v-Src was incubated with GST fusion pro-
teins containing the NTDs of EWS, TLS, or hTAFII68. An aliquot
of input (10%) and the pellet from the various GST-TET (NTD)
pull-downs were analyzed on a 10% SDS^polyacrylamide gel. The
bound v-Src protein was visualized by £uorography. The nature of
the GST fusion proteins is indicated above the panel. The positions
of migration of the molecular weight markers is indicated to the
left. v-Src protein is indicated by an arrow to the right. Lane 1,
10% input; lane 2, GST alone; lane 3, GST-EWS NTD; lane 4,
GST-TLS NTD; lane 5, GST-hTAFII68 NTD. B: Quantitation of
the amounts of GST fusion proteins used in the GST pull-down as-
say. The GST fusion proteins utilized in the pull-down assays were
fractionated on 15% SDS^PAGE and visualized by Coomassie blue
staining. Lane 1, GST alone; lane 2, GST fusion EWS NTD; lane
3, GST fusion TLS NTD; lane 4, GST fusion hTAFII68 NTD.
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ity-precipitated with Ni2þ-NTA resin. A⁄nity-puri¢ed
hTAFII68 (NTD) proteins were fractionated by SDS^PAGE,
transferred to PVDF membrane, and immunoblotted with an
anti-Flag antibody to quantitate the amount of protein in
each sample (Fig. 1D, top panel). To detect tyrosine phos-
phorylation, the anti-phosphotyrosine antibody 4G10 was
used as a probe. Signi¢cant amounts of tyrosine phosphory-
lation were detected on hTAFII68 (NTD) protein isolated
from cells that had received the v-Src cDNA (Fig. 1D, bottom
panel), but not in cells in which an empty expression vector
had been introduced. These results demonstrate that v-Src is
capable of modifying hTAFII68 (NTD) by tyrosine phosphor-
ylation in vitro and in vivo.
3.2. hTAFII68 (NTD) interacts with v-Src in vitro and in vivo
Given that EWS (NTD) contains interaction motif(s) for
v-Src SH3 and SH2 domains [29,30], the relatedness of the
EWS and hTAFII68 NTDs, and the results presented above
indicating that hTAFII68 is a substrate for Src, we assessed
whether hTAFII68 could also interact with v-Src. To test for
the potential interaction between hTAFII68 (NTD) and v-Src,
in vitro pull-down assays were performed using bacterially
expressed GST fusion hTAFII68 (NTD), TLS (NTD), and
EWS (NTD) proteins and radiolabeled full-length v-Src gen-
erated in an in vitro translation reaction. In this assay, GST
did not show any non-speci¢c association with v-Src (Fig. 2A,
lane 2). In addition, in vitro translated luciferase did not bind
to immobilized GST, GST-EWS (NTD), GST-TLS (NTD), or
GST-hTAFII68 (NTD), indicating that the interaction be-
tween v-Src and hTAFII68 (NTD) is speci¢c (H.J. Lee and
J. Kim, data not shown). The NTD of EWS pulled down v-
Src con¢rming this previously reported interaction [29] (lane
3). Both other members of the TET family, TLS and
hTAFII68, also pulled down v-Src, albeit with di¡erent e⁄-
ciencies (compare lanes 4 and 5 to lane 3). For the purpose of
the current study, we focused on better de¢ning and charac-
Fig. 3. Association of hTAFII68 (NTD) with v-Src in vivo. A: Subcellular localization of hTAFII68-TEC in cells. COS-7 cells grown on cover-
slips were transfected with mammalian expression vectors encoding Flag-tagged hTAFII68-TEC. Subcellular distribution of hTAFII68-TEC was
analyzed with anti-Flag antibody. B: Subcellular localization of v-Src in cells. COS-7 cells grown on coverslips were transfected with mammali-
an expression vectors encoding GFP-tagged v-Src. Subcellular distribution of GFP-tagged v-Src was analyzed by £uorescent microscopy for
green £uorescence. The white arrowheads show perinuclear regions with high concentrations of v-Src. The black arrowheads point out the £uo-
rescent nuclei indicating the possible presence of v-Src in nucleus. C: Co-a⁄nity puri¢cation of hTAFII68 (NTD) with v-Src from 293T cells.
Forty-eight hours after cotransfection of 293T cells with 10 Wg of pcDNA3/v-Src and either 10 Wg of pcDNA3/GST or pcDNA3/GST-
hTAFII68 (NTD), cell extracts were prepared as described in Section 2 and a⁄nity-precipitated with glutathione-Sepharose beads. After frac-
tionation on 10% SDS^PAGE, the a⁄nity precipitates were analyzed for the presence or absence of v-Src protein by Western blotting utilizing
an anti-Src antibody (H-12, Santa Cruz Biotechnology). The positions of the molecular weight markers are indicated to the left and the posi-
tion of migration of v-Src is indicated by an arrow to the right. D: The interaction between hTAFII68 (NTD) and v-Src is direct. Bacterially
produced His6-tagged v-Src protein was incubated with GST alone or GST-hTAFII68 (NTD) at 4‡C for 1 h. After extensive washing, bound
v-Src was assessed by SDS^PAGE and Western blot analysis with an anti-v-Src antibody (H-12, Santa Cruz Biotechnology). Lane 1, 15% in-
put; lane 2, GST alone; lane 3, GST-fusion hTAFII68 (NTD).
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terizing the interaction between hTAFII68 (NTD) and v-Src.
The amounts of GST fusion proteins utilized in this assays
were fractionated on 15% SDS^PAGE and visualized by
Coomassie blue staining and revealed that similar amounts
of protein had been used in the pull-down assay (Fig. 2B).
The existence of hTAFII68 (NTD)-v-Src complex in vitro
was further supported by the intracellular localization of
hTAFII68 and v-Src in COS-7 cells. For this purpose, we
constructed plasmid expressing Flag-tagged hTAFII68-TEC
fusion protein. A pCMV Tag2a-Flag-hTAFII68-TEC was in-
troduced into COS-7 cells and the subcellular localization of
the protein was detected by immunocytochemistry. In transi-
ently transfected cells, the Flag-tagged hTAFII68-TEC protein
was clearly localized in the nucleus (Fig. 3A). In addition, we
also transfected hTAFII68 or TEC constructs into COS-7 cells
and detected both proteins in the nucleus (H.J. Lee and
J. Kim, data not shown and manuscript in preparation). To
further examine a possible colocalization of v-Src and
hTAFII68-fusion protein, we transfected pEGFP(N1)/v-Src
(a mammalian expression vector encoding a fusion of v-Src
and EGFP, in which the v-Src coding region was cloned into
the 5P end of EGFP) into COS-7 cells to determine its intra-
cellular localization by using green £uorescence. Consistent
with previous reports [44^46], the majority of v-Src proteins
localize in the cytoplasm (Fig. 3B). In addition, signi¢cant
amounts of myristoylated v-Src proteins were associated
with the perinuclear membrane, as reported previously [47]
(Fig. 3B, white arrowheads). Furthermore, consistent with
another report [48], non-membrane-anchored v-Src was also
detected in the nucleus, indicating the possible presence of
myristoylation-de¢cient v-Src proteins in this cellular com-
partment (Fig. 3B, black arrowheads). Thus, these results
demonstrate that hTAFII68 and v-Src proteins partially colo-
calized in cells.
To determine whether the interaction between hTAFII68
(NTD) and v-Src occurred in vivo, we performed co-a⁄nity
precipitations following transfection of 293T cells with expres-
sion vectors driving the synthesis of both proteins. For these
assays, two mammalian expression vectors containing the
NTD of hTAFII68 fused to GST (pcDNA3/GST-hTAFII68
(NTD)) and the GST domain alone (pcDNA3/GST) were
cotransfected with pcDNA3/v-Src into 293T cells. Cells were
lysed 48 h after transfection and GST or GST-hTAFII68
(NTD) fusions were a⁄nity-precipitated with glutathione
beads. Immunoblottings performed on the eluents using an
anti-Src antibody revealed that v-Src is speci¢cally coprecipi-
tated with GST-hTAFII68 (NTD), but not with GST alone
(Fig. 3A). These results demonstrate that hTAFII68 (NTD)
and v-Src can associate in vivo.
However, neither the in vivo interaction in mammalian cells
nor the GST pull-down assay using in vitro translated v-Src
addresses whether this interaction is direct or occurs via an
intermediate bridging protein. To investigate this, v-Src was
expressed as a His6-containing fusion protein in E. coli and
puri¢ed by Ni2þ-NTA-agarose resin. A GST pull-down assay
was then performed using recombinant His6-v-Src with
GST or GST-hTAFII68 fusion protein which had also been
produced in E. coli. Following extensive washing, the amount
of v-Src retained was determined by Western blotting using
an anti-v-Src antibody. As shown in Fig. 3B, bacterially
produced GST-hTAFII68 (NTD) protein interacts with bac-
terially produced v-Src, indicating that the hTAFII68
(NTD)-v-Src interaction appears not to require an adapter
protein.
3.3. The C-terminal part of hTAFII68 (NTD) is involved in
v-Src interaction
To de¢ne the domain within hTAFII68 (NTD) required for
interacting with v-Src, in vitro binding experiments were per-
formed with a series of hTAFII68 (NTD) deletion mutants.
The structures of the hTAFII68 (NTD) deletion mutants used
in this study are shown schematically in Fig. 4A. We ¢rst
performed GST pull-down assays using in vitro translated
[35S]methionine-labeled v-Src protein, together with deletion
mutants of hTAFII68 (NTD). As shown in Fig. 4B, v-Src
bound strongly to GST-hTAFII68 (75^159), but interacted
weakly with GST-hTAFII68 (1^72) and GST-hTAFII68
(29^105). The GST fusion hTAFII68 (NTD) showed a similar
Fig. 4. Mapping the hTAFII68 (NTD) region that interacts with
v-Src. A: Schematic representation of the GST-hTAFII68 (NTD)
fusion proteins and their ability to bind to v-Src. Numbers refer to
amino acid residues. Strength of binding is indicated in a semi-
quantitative fashion (++++, strong binding; +/3, weak binding; 3,
no binding). B: Strong binding of v-Src to the GST-hTAFII68 (75^
159). Recombinant GST-hTAFII68 (NTD) deletion mutants were in-
cubated with [35S]methionine-labeled v-Src protein. Following GST
pull-down assays, the bound proteins were eluted with SDS loading
bu¡er and analyzed by 15% SDS^PAGE. The positions of migra-
tion of molecular weight markers and of v-Src are indicated. Lane
1, 10% input; lane 2, GST alone; lane 3, GST fusion hTAFII68
(1^72); lane 4, GST fusion hTAFII68 (29^105); lane 5, GST fusion
hTAFII68 (75^159). C: Coomassie blue staining of various GST
fusion hTAFII68 deletions. The amounts of GST fusion proteins uti-
lized in this assays were fractionated on a 15% SDS^polyacrylamide
gel and visualized by Coomassie blue staining. Lane 1, GST alone;
lane 2, GST fusion hTAFII68 (1^72); lane 3, GST fusion hTAFII68
(29^105); lane 4, GST fusion hTAFII68 (75^159).
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binding pro¢le as GST-hTAFII68 (75^159), indicating that
amino acids 75^159 of the hTAFII68 (NTD) are su⁄cient
for v-Src interaction (H.J. Lee and J. Kim, unpublished
data). Our experiments do not address whether the observed
in vitro interaction between hTAFII68 (NTD) and v-Src is
direct or indirect. As shown in Fig. 4C, the amounts of indi-
vidual GST fusion proteins utilized in this assays were similar.
3.4. The SH3 and SH2 domains of v-Src interact with
hTAFII68 (NTD)
To determine whether the SH3 and/or SH2 domains of
v-Src were required to bind to hTAFII68 (NTD), a series of
GST pull-down assays were performed with GST fusions of
v-Src SH2 and SH3 domains. The important v-Src functional
regions for protein^protein interaction, such as the SH3 and
SH2 domains, were individually expressed as GST fusion pro-
teins in E. coli, puri¢ed and coupled to glutathione-Sepharose
beads. Following incubation with [35S]methionine-labeled
hTAFII68 (NTD) protein and extensive washing, the amount
of hTAFII68 (NTD) retained was determined by SDS^PAGE
and autoradiography. As shown in Fig. 5A, the GST fusion
protein containing the v-Src SH3 domain was able to retain
hTAFII68 (NTD). The GST fusion protein containing the
SH2 domain also bound to hTAFII68 (NTD) but retained
much less protein (Fig. 5A, compare lanes 3 and 4). However,
hTAFII68 (NTD) did not interact with GST alone (lane 2).
These results suggest that the association of hTAFII68 (NTD)
with v-Src can be mediated independently through the SH3 or
SH2 domains albeit the SH3 domain appears to have a higher
a⁄nity. The amounts of GST fusion proteins utilized in these
assays were similar (Fig. 5B).
3.5. Di¡erential binding of hTAFII68 (NTD) to SH3 domains
Since hTAFII68 (NTD) can associate with the SH3 domain
of v-Src (Fig. 5A), we assessed whether hTAFII68 (NTD)
could interact with other SH3 domain-containing proteins.
[35S]Methionine-labeled hTAFII68 (NTD) was prepared by
in vitro transcription and translation, and GST pull-down
assays were performed with GST fusion proteins containing
the SH3 regions of various protein tyrosine kinases or adapter
proteins. According to previous reports, EWS/WT1 protein
was tightly associated with fusion proteins containing the
c-Abl and v-Src SH3 domains [29,30]. In addition, a small
amount of binding was also noted with the SH3 domain of
Fig. 5. Involvement of the SH3 and SH2 domains of v-Src in
the interaction of hTAFII68 (NTD). A: Binding of hTAFII68
(NTD) to the v-Src SH3 and SH2 domains. In vitro generated
[35S]methionine-labeled hTAFII68 (NTD) protein was incubated
with GST, GST fusion SH3, or GST fusion SH2 domains bound to
glutathione-Sepharose beads. An aliquot of the input and the pellets
from GST pull-down assays were analyzed by 10% SDS^PAGE,
and the bound hTAFII68 (NTD) proteins were detected by £uoro-
graphy. The position of migration of hTAFII68 (NTD) is indicated
by an arrow to the right. Lane 1, 10% input; lane 2, GST alone;
lane 3, GST fusion v-Src SH3 domain; lane 4, GST fusion v-Src
SH2 domain. B: Coomassie blue staining of GST, GST fusion v-Src
SH3, and v-Src SH2 domains. The amounts of GST fusion proteins
utilized in this assays were fractionated on 10% SDS^PAGE and vi-
sualized by Coomassie blue staining. Lane 1, GST alone; lane 2,
GST fusion v-Src SH3 domain; lane 3, GST fusion v-Src SH2 do-
main.
Fig. 6. The Crk(N) SH3 domain is capable of recognizing hTAFII68
(NTD). A: Binding analysis of hTAFII68 (NTD) to various SH3
domains. A number of GST-SH3 fusion proteins were expressed in
E. coli, a⁄nity puri¢ed from bacterial lysates, and coupled to gluta-
thione-Sepharose beads. [35S]Methionine-labeled hTAFII68 (NTD)
was incubated with GST fusion proteins containing the SH3 regions
of v-Src, c-Abl, Grb(C), Ras-GAP, Crk(N), or PLC-Q. The proteins
binding to the SH3 fusion proteins were eluted with SDS sample
bu¡er, fractionated on 10% SDS^PAGE, and visualized by £uorog-
raphy. The GST-SH3 domains from various proteins are indicated
at the top of the panel. The position of migration of hTAFII68
(NTD) is indicated to the right. Lane 1, 25% input; lane 2, GST
alone; lane 3, GST-v-Src SH3 domain; lane 4, GST-c-Abl SH3 do-
main; lane 5, GST-Grb(C) SH3 domain; lane 6, GST-Ras-GAP
SH3 domain; lane 7, GST-Crk(N) SH3 domain; lane 8, GST-PLC-Q
SH3 domain. B: Coomassie blue staining of various GST fusion
SH3 domains. The amounts of GST fusion proteins utilized in these
assays were fractionated on 15% SDS^PAGE and visualized by
Coomassie blue staining. Lane 1, GST alone; lane 2, GST-v-Src
SH3 domain; lane 3, GST-c-Abl SH3 domain; lane 4, GST-Grb(C)
SH3 domain; lane 5, GST-Ras-GAP SH3 domain; lane 6, GST-
Crk(N) SH3 domain; lane 7, GST-PLC-Q SH3 domain.
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Crk(N) [29,30]. We assessed the ability of hTAFII68 (NTD) to
interact with a number of SH3 domains isolated from various
sources. The hTAFII68 (NTD) polypeptide was retained by
fusion proteins containing the v-Src and Crk(N) SH3 do-
mains, but not signi¢cantly to the c-Abl, Grb(C), Ras-GAP,
or PLC-Q SH3 domains (Fig. 6A, lanes 3^8). Thus, hTAFII68
binds di¡erentially to the SH3 domains tested and provides a
molecular selectivity that can distinguish among SH3 do-
mains. The lack of reactivity of several di¡erent SH3 domains
with hTAFII68 suggests that the hTAFII68 interaction is spe-
ci¢c and that the di¡erent types of SH3 domains are not
equivalent with respect to hTAFII68 binding activity. The
amounts of GST fusion proteins utilized in this assays were
equivalent (Fig. 6B).
3.6. v-Src activates hTAFII68 (NTD)-mediated transactivation
Given the physical interaction between hTAFII68 (NTD)
and v-Src in vivo (Fig. 3A) and having identi¢ed hTAFII68
(NTD) as an in vivo target of v-Src (Fig. 1D), we next mea-
sured the e¡ect of v-Src expression on the transcriptional ac-
tivation property of hTAFII68 (NTD). This was done by ex-
amining gene expression from a luciferase-based reporter
plasmid cotransfected with pcDNA3/Gal4-hTAFII68 (NTD)
with or without cotransfection of pcDNA3/v-Src into C33A
cells. Consistent with previously reported data [42], introduc-
tion of Gal4-hTAFII68 (NTD) into C33A cells signi¢cantly
activated transcription (V20-fold) from pG5 luc, a reporter
plasmid containing the E1B minimal promoter harboring ¢ve
copies of Gal4 DNA binding sites and driving synthesis of
Renilla luciferase (Fig. 7A, compare bar 2 to bar 1). Interest-
ingly, the presence of v-Src augmented hTAFII68 (NTD)-
mediated transactivation ¢ve-fold (Fig. 7A, compare bars
3^5 to bar 2). v-Src had no signi¢cant e¡ect on the transcrip-
tional response from pG5 luc when introduced in the absence
of hTAFII68 (NTD) (H.J. Lee and J. Kim, data not shown).
To investigate the e¡ect of v-Src on hTAFII68 (NTD)-medi-
ated transcription, two kinase-inactivated v-Src mutants,
v-Src vkinase and v-Src R295K, were used in the transfection
Fig. 7. Modulation of hTAFII68 (NTD)-mediated transactivation by v-Src. A: Stimulation of transactivation activity of hTAFII68 (NTD) by
v-Src. C33A cells were transfected with 2 Wg of Gal4 or Gal4-hTAFII68 (NTD) plasmids alone or together with increased amounts of expres-
sion plasmids for v-Src (1, 3, and 5 Wg) (bars 3^5). Cells were harvested 48 h post transfection in passive lysis bu¡er, and 10 Wl was used in
the luciferase assay. Values are expressed as mean increasesW S.D. relative to a value of 1 which was set from the reporter plasmid transfection
alone. Results shown are means from two independent experiments performed in duplicate. B: The stimulation of hTAFII68 (NTD)-mediated
transactivation by v-Src is kinase-dependent. Two micrograms of Gal4 or Gal4-hTAFII68 (NTD) expression plasmids were cotransfected with
1 Wg of v-Src or v-Src kinase mutants into C33A cells, respectively. Cells were harvested 48 h post transfection in passive lysis bu¡er, and 10 Wl
was used in the luciferase assay. Luciferase activity was measured and normalized to Renilla luciferase activity. The relative transactivation val-
ues obtained with Gal4-hTAFII68 (NTD) was taken as 100%. Results shown are means from two independent experiments performed in dupli-
cate. The standard deviation for each experiment is shown by an error bar. C: Inhibition of hTAFII68 (NTD)-mediated transactivation by
dominant-negative v-Src. C33A cells were cotransfected with 2 Wg of Gal4 or Gal4-hTAFII68 (NTD) expression plasmids and increasing
amounts (1, 3, and 5 Wg) of dominant-negative v-Src mutant, v-Src R295K. Luciferase activity was measured and normalized to Renilla lucifer-
ase activity. The relative transactivation values obtained with Gal4-hTAFII68 (NTD) was taken as 100%. Results shown are the mean from
two independent experiments performed in duplicate. The standard deviation for each experiment is shown by an error bar.
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assay (Fig. 7A). v-Src vkinase and v-Src R295K are a kinase
domain deletion mutant and a kinase-negative mutant, the
latter harboring a lysine to arginine missense mutation in
the kinase domain. As shown in Fig. 7B, both mutants failed
to stimulate transcription mediated by hTAFII68 (NTD), sug-
gesting a requirement for the kinase activity of v-Src for this
observed e¡ect (compare bars 4 and 5 to bar 3).
To assess the possibility that a dominant-negative form of
v-Src can block hTAFII68 (NTD)-mediated transcription, we
determined the e¡ect of v-Src R295K on hTAFII68 activity.
When cells were cotransfected with Gal4-hTAFII68 (NTD)
and v-Src R295K, hTAFII68 function was inhibited up to
65% in a dose-dependent manner (Fig. 7C). Taken together,
these results suggest that the transcriptional activation func-
tion of hTAFII68 (NTD) can be signi¢cantly increased by
activation of Src, that this e¡ect is dependent on Src kinase
activity, and cellular Src activity is likely to be important for
hTAFII68 (NTD)-mediated transcription activation.
4. Discussion
In this report, we demonstrate that the transcriptional
properties of hTAFII68 can be modulated by the Src protein
tyrosine kinase. The hTAFII68 polypeptide shows extensive
similarities to the EWS and TLS proteins [17,49]. The two
latter genes, which were originally identi¢ed as the amino-
terminal portions of translocation-generated fusion genes in
Ewing’s sarcomas and myxoid liposarcomas, encode putative
RNA binding proteins containing a central RNA binding do-
main and three glycine-, arginine-, and proline-rich motifs
[50,51]. We have previously documented that EWS/WT1 is
phosphorylated by protein tyrosine kinases and this modi¢-
cation regulates DNA binding, self-association, and transacti-
vation of the fusion protein [29,30,51], demonstrating that
EWS (NTD)-mediated transcription could be regulated by
signaling pathways under control of cytoplasmic kinases. In
contrast to our understanding of EWS function, the regula-
tion of hTAFII68 remains poorly characterized.
Our results demonstrate that the hTAFII68 (NTD) contains
several potential tyrosine phosphorylation sites (Fig. 1A,C)
and is a substrate for v-Src in vitro and in vivo (Fig. 1B,D).
Src kinases have been reported to regulate a variety of cell
functions, including cell cycle progression, growth, survival,
and migration [24,52]. Studies using human tumor tissues
and tumor-derived cell lines have demonstrated that enhanced
tumorigenicity in vivo is correlated with elevated c-Src expres-
sion and tyrosine phosphorylation [53]. Our results suggest
that v-Src resides upstream of hTAFII68 and modulates
hTAFII68 function.
The ¢nding that a dominant-negative form of v-Src blocks
hTAFII68 (NTD)-mediated transactivation (Fig. 7C) suggests
that endogenous Src activity is required for hTAFII68 acti-
vation in vivo. It is interesting to note that signaling through
v-Src is known to perturb the transcription of cellular pro-
teins. For instance, studies using the activated viral form of
the Src protein have demonstrated that the ectopic introduc-
tion of v-Src can stimulate or repress the amounts of tran-
scripts encoding a wide variety of cellular proteins [54^63]. In
addition, other data have shown that transformation of cells
by non-nuclear oncoproteins leads to deregulated transcrip-
tion in the nucleus. For example, Ha-Ras, a cytoplasmic sig-
naling protein, is critical for the activation of the Egr-1 pro-
moter and Cox-2 gene (also known as TIS10 and
prostaglandin synthase) in v-Src-transformed cells [64,65].
Likewise, the serine/threonine kinase c-Raf is critical for the
expression of Egr-1 but plays no role in the activation of
Cox-2 [66,67]. Our studies provide a molecular mechanism
for a speci¢c case ^ that is, of Src signaling to hTAFII68.
We have recently shown that the NTD of EWS contains six
PxxP regions, which have been shown to interact with the
SH3 domains [29,30]. It has been well documented that SH3
domains mediate protein^protein interactions involved in the
signal transduction, cytoskeletal organization, and subcellular
localization of proteins [68,69]. In fact, these domains consists
of two anti-parallel L-sheets packed at right angles to one
other [70,71]. Two SH3 variable loops, the RT and n-Src
loops, £ank a ligand binding region formed by the contribu-
tion of residues that are well conserved in the SH3 family and
this region binds proteins with the consensus sequence PxxP
[70,72^77]. We have previously reported the presence of two
SH3 domain-interacting motifs within the proline-rich region
of EWS (NTD) that correspond to the consensus motif
(PxxxxPxxP) identi¢ed in a number of c-Abl targets [30]. In
addition, three proline-rich motifs of EWS (NTD) could pro-
vide binding sites for the v-Src SH3 domain [29].
The interaction between hTAFII68 (NTD) and v-Src SH3
domain was unexpected as hTAFII68 (NTD) does not contain
any proline-rich region corresponding to the consensus motif
(PxxP) identi¢ed in a number of SH3 domain-interacting pro-
teins. However, although SH3 domains are well established
protein modules that recognize extended proline-rich sequen-
ces, a modi¢cation of this theme has recently been reported
[78,79]. For example, Mongiovi et al. reported that sequences
with the consensus PxxDY, derived from the e3b1/Abi-1 and
RN-tre proteins, interact with the Eps8 SH3 domain [78]. In
addition, Kato et al. [80] and Lewitzky et al. [81] reported that
sequences with the consensus Px[VI][DN]RxxKP, from the
UBPY, Gab1, AMSH, and SLP-76 proteins, bind to the
SH3 domains in the Hbp, STAM, and Grb2 proteins. Simi-
larly, the SH3 domain of p53BP2 interacts with a peptide
sequence in p53 that is not proline-rich [82]. It is therefore
likely that the hTAFII68 (NTD)/Src interaction falls into the
class of SH3 interactions in which the partner lacks the pro-
totypical PxxP motif.
Using recombinant proteins in a GST pull-down assay, we
showed that hTAFII68 harbors at least two independent bind-
ing sites for the v-Src protein (Fig. 4B): a high a⁄nity binding
site located in hTAFII68 (75^159) and a low a⁄nity binding
site in hTAFII68 (1^72). The binding observed with hTAFII68
(29^105) may be due to a third site, or to the presence of the
low a⁄nity site detected with hTAFII68 (1^72). Interestingly,
v-Src also contains two independent hTAFII68 (NTD)-inter-
acting motifs ^ the SH3 and SH2 domains (Fig. 5A). These
results suggest that the association of v-Src with hTAFII68
(NTD) could be mediated by two di¡erent domains on each
molecule or that the stoichiometry of the interacting proteins
is greater than 1:1. Further experiments will be required to
distinguish among these possibilities.
It has been shown that several SH3-containing adapter pro-
teins, such as Crk, Grb2, and Nck, bind to the proline-rich
region immediately C-terminal of the tyrosine kinase domain
[83^85]. These adapter proteins play critical roles in the as-
sembly of signaling complexes [84]. In general, such an adapt-
er binds to a tyrosine-phosphorylated protein through its SH2
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domain and a proline-rich protein through its SH3 domain
and these simultaneous bindings allow the relay of a signal
from one partner to the other [69]. Because the SH3 domain
of Crk binds to hTAFII68 (Fig. 6A), this adapter protein may
recruit hTAFII68 to speci¢c signaling pathways.
Our ¢nding that v-Src can phosphorylate and associate with
hTAFII68 (NTD) in vitro and in vivo indicates that v-Src
resides upstream of hTAFII68. However, it is not clear how
the cytoplasmic membrane-anchored v-Src regulates activity
of nuclear-localized hTAFII68. One possibility that could ex-
plain these v-Src e¡ects on hTAFII68 (NTD) function is that
the hTAFII68 (NTD)-mediated transactivation is modulated
by non-membrane-anchored v-Src. It is well documented that
the N-terminal glycine residue of the Src kinase is cotransla-
tionally myristoylated during protein synthesis [44,86^89] and
this fatty acid modi¢cation is required for its plasma mem-
brane association [44^46]. However, although myristoylation
of c- or v-Src is required for association with the cytoplasmic
membrane, not all myristoylated Src proteins are associated
with the plasma membrane [90,91]. According to a previous
report, signi¢cant amounts of myristoylated c- and v-Src
kinases are also associated with the perinuclear membrane
[47]. Furthermore, it has been estimated that as much as
16% of v-Src may not be modi¢ed in vivo [87]. Interestingly,
myristoylation-de¢cient Src proteins do not simply lose the
ability to bind with a high a⁄nity to plasma membrane-asso-
ciated receptor [88,92^94], but they also require the ability to
translocate inside the nucleus [48]. Consistent with these re-
ports, we also found that some v-Src protein is associated
with the perinuclear membrane and present in the nucleus
(Fig. 3B).
The other possibility that could explain these v-Src e¡ects
on hTAFII68 (NTD)-mediated transactivation is that Src pro-
tein ¢rst a¡ects induction or modi¢cation of nuclear transcrip-
tional regulatory proteins which subsequently modulate trans-
activation properties of hTAFII68. In fact, activation of gene
expression is a common consequence following stimulation of
receptor or non-receptor tyrosine kinases by growth factors
such as epidermal growth factor, platelet-derived growth fac-
tor, or colony-stimulating factor 1 [24,95]. We also have
shown that hTAFII68 is able to bind to the SH2 or SH3
domains of several signaling molecules. Although the func-
tional signi¢cance of these interactions still remains unde¢ned,
it is conceivable that other signaling proteins can also modu-
late hTAFII68 functions.
hTAFII68 was originally identi¢ed on the basis of its asso-
ciation with a distinct TFIID subpopulation [17]. TFIID is
the main sequence-speci¢c DNA binding components of the
RNA polymerase II transcription machinery [96,97]. It is a
multiprotein complex composed of the TBP and TBP-associ-
ated factors and is the factor that nucleates preinitiation com-
plex formation on RNA polymerase II-mediated transcription
[98]. Additionally, hTAFII68 is also associated with another
multiprotein complex, the human RNA polymerase II com-
plex [99]. Interestingly, hTAFII68 is able to enter into the
preinitiation complex together with RNA polymerase II, sug-
gesting that hTAFII68 has a role in transcription initiation
and/or elongation. Thus, the hTAFII68 fusion product in hu-
man cancers may stimulate transcription in a similar fashion
to that proposed for hTAFII68. In addition, it is conceivable
that hTAFII68 (NTD) functions as a bridging factor by me-
diating a stable interaction between DNA and the transcrip-
tion apparatus. Furthermore, it would also be interesting to
attempt to determine if ectopic expression of v-Src could mod-
ulate the transcription initiation and/or elongation through
hTAFII68 modi¢cation.
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